BioNTech Stock Gains 7% On Reports Of Plan To Seek EUA For Covid-19 Booster Shot

Shares of BioNTech SE (BNTX) are gaining over 7% on Monday morning on reports that the German pharma company and its partner Pfizer (PFE) is planning to to seek US Food and Drug Administration emergency use authorization for a coronavirus vaccine booster shot for people 18 and older.

BNTX is currently trading at $232.64, up $16.00 or 7.39%, on the Nasdaq.

According to reports, the request could come as soon as this week, and is expected to win FDA's approval.

Last month, Pfizer and BioNTech said that results from a late-stage trial, which evaluated the efficacy and safety of a booster dose of their COVID-19 vaccine in more than 10,000 individuals 16 years of age and older, showed a relative vaccine efficacy of 95.6% compared to those who did not receive a booster.

In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID-19 to the high levels achieved after the second dose.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT